The ICMR’s National Task Force for Covid-19 has decided against including antiviral drug Molnupiravir in the Clinical Management Protocol for Covid-19 as of now, official sources said on Tuesday.
The experts of the task force cited safety concerns and argued that Molnupiravir was not of much benefit in Covid treatment to arrive at the decision in a meeting held on Monday.